2AI-Sarraf M, LeBlanc M, Girl PG, et al. Chemoradiotherapy versus ra- diotherapy in patients with advanced nasopharyngeal cancer:phase ill randomized Intergroup study 0099 [ J ]. J Clin Oncol, 1998,16 ( 4 ) : 1310-1317.
3Kwong DL, Sham JS, Au GK, et al. Concurrent and adjuvant chemo- therapy for nasopharyngeal carcinoma:a factorial study [ J]. J Clin On- col,2004,22 (13) :2643-2653.
4Chan AT,Leung SF,Ngan RK,et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregion- ally advanced nasopharyngeal carcinoma [ J ]. J Natl Cancer Inst, 2005,97 (7) :536-539.
5Hui EP, Ma BB, Leung SF, et al. Randomized phase II trim of concur- rent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma [ J ]. J Clin Oncol, 2009,27 ( 2 ) : 242-249.
6Wang R, Wu F, Lu H, et al. Definitive intensity-modulated radia- tion therapy for nasopharyngeal carcinoma: long--term outcome of a multicenter prospective study[J]. J Cancer Res Clin Oncol, 2013, 139(1):139-145.
7Wu F, Wang R, Lu H, et al. Concurrent chemoradiotherapy in lo- coregionally advanced nasopharyngeal carcinoma: Treatment out- comes of a prospective, multicentric clinical study[J]. Radiother On- col, 2014, 112(1):106-111.
8A1-Sarraf M, LeBlanc M, Girl PG, et al. Chemoradiotherapy ver- sus radiotherapy in patients with advanced nasopharyngeal cancer: phase HI randonfized Intergroup study 0099[J]. J Clhl Oncol, 1998, 16(4):1310-1317.
9Huang PY, Can KJ, Guo X, et al. A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced naso- pharyngeal carcinoma[I]. Oral Oncology, 2012, 48 (10) : 1038-1044.
10Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal car- cinoma: a phase 3 multicentre randomised controlled trial[J]. TheLancet Oncology, 2012, 13(2):163-171.
